Teva stock climbs on vet-med deal news; Medicines Co. sues Teva over Angiomax again;

> Teva Pharmaceutical Industries stock climbed to the highest level in at least 15 years, as a unit may obtain the license for treatments of veterinary pathogens. Report

> Medicines Co. is suing Teva Parenteral Medicines and Pliva Hrvatsk claiming infringement of another patent pertaining to the company's anti-clotting agent Angiomax. Release

> GlaxoSmithKline chief executive Andrew Witty has been appointed president of EFPIA, a leading industry association in Europe. Release

> European regulators have approved an intravenous version of Pfizer's high blood pressure drug Revatio, which has the same active ingredient as ED remedy Viagra. Report

> The healthcare reform bill currently winding its way through the U.S. Congress may make the shares of some health and drug companies--including Amgen--more attractive. Report

Biotech News

> New York-based Paul Capital Healthcare announced this morning that it will provide up to $100 Million to Phase III Development Company--"P3D"--which was recently established to help manage and fund late-stage clinical trials in the European Union. Story

> Dainippon Sumitomo has filed for FDA approval of its prospective blockbuster schizophrenia drug lurasidone, beating its own timetable as the Japanese pharma giant stays on course toward an expected 2011 market launch. Report

> The days of giant R&D organizations orchestrating every step in the development of new drugs have ended. And you need only look at today's Wall Street Journal for another telling example of the trend toward outsourcing and partnering. Story

Biotech Research News

> A team of researchers drawn from Cornell University, Colorado State University and the University of California, San Diego have tapped a new federal grant to study whether an innovative stem cell technique can regenerate cartilage. Story

> Scientists at the Gladstone Institute of Virology and Immunology say they've made a key discovery that should help accelerate work on an effective topical microbicide to stop the sexual transmission of AIDS. Report

 > Scientists from the University of Pennsylvania in Philadelphia have good news for prostate cancer patients: The discovery of a super-molecule that seeks and destroys prostate cancer cells. And this finding holds promise for men with both early and late stages of the disease. Story

> The NIH grabbed $10 billion of taxpayers' funds funneled through the stimulus bill, and NIH chief Francis Collins says the money was used to save or create 50,000 research jobs. In many cases, he adds, the extra funds have kept America's scientists in American labs. Story

> Researchers in the UK are preparing to begin a human trial of a small-diameter artificial artery crafted from polymers. Up to now narrow artificial arteries have often failed to work in humans. But this new artery, developed at London's Royal Free Hospital, mimics nature and provides the pulse needed to avoid clotting. Story

And Finally... Casey Johnson, heiress to the Johnson & Johnson business empire, has died, a spokesman for the family and police said. Report